Oxygen Biotherapeutics, Inc. (OXBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

• Publication date: March 2011

Oxygen Biotherapeutics, Inc. (OXBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile Summary Oxygen Biotherapeutics, Inc.(OBI) is a biotechnology company, which develops products that focus on oxygen delivery to tissue. The company's products focus on various unmet medical needs including traumatic brain injury, decompression sickness, wound treatment, carbon monoxide poisoning, surgical iatrogenic embolism, emergency ox...

Oxygen Biotherapeutics, Inc. (OXBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Oxygen Biotherapeutics, Inc.(OBI) is a biotechnology company, which develops products that focus on oxygen delivery to tissue. The company's products focus on various unmet medical needs including traumatic brain injury, decompression sickness, wound treatment, carbon monoxide poisoning, surgical iatrogenic embolism, emergency oxygen treatment, spinal cord injury and cosmetic problems. The company's product, Oxycyte, is a perfluorocarbon therapeutic oxygen carrier that was developed to improve oxygen delivery to damaged tissues. The company has developed a range of topical perfluocarbon gels based on the Oxycyte compound that finds use in surgical and similar medical situations. The company has entered into several partnerships and collaborations to advance its various products under development through commercialization. OBI is headquartered in Durham, North Carolina, the US.

Oxygen Biotherapeutics, Inc. (OXBT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you an in-depth data and trend analysis of the company’s mergers and acquisitions (M&A) and financings. The report provides detailed information on M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions registered by the company over a five year period. The report portrays detailed comparative data on the number of deals and their value subdivided by deal types, markets, and regions, besides highlighting the company's major recent financial deals.

Data presented in this report was derived from GlobalData’s proprietary in-house Pharmaceuticals and Healthcare eTrack deals database and primary and secondary research.

Scope

- Financial Deals - Analysis of the company’s financial deals including M&A, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information on the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information on the number of deals and value reported by the company by type such as M&A, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region for North America, Europe, the Middle East and Africa and South and Central America.
- Deals by Market - Chart and table showing information on the number of deals and value reported by the company, by market.
- Major Recent Deals - Information on the company's major recent financial deals. Each such deal has a brief summary, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
- Business Description - A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key Competitors – A list of key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements.
- The profile analyzes the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divesture strategy
- Deals are presented from the company’s core business segments’ perspective to help you understand its corporate strategy

Access detailed information about the company’s recent financial deals that enables you to understand the key deals which have shaped the company
- Major recent deals are presented in detail, which provides information on each deal’s brief summary, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and their biographies and key competitors.

Stay up to date on the major developments affecting the company
- Recent developments in the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research.
- Key elements such as break up of deals by categories and information on detailed major deals are incorporated in the profile to assist your academic or business research needs.

Therapy Industry in the United States

Table of Contents


Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 6
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011 7
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011 8
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011 9
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011 10
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 11
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 12
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011 13
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 14
Oxygen Biotherapeutics Enters Into An Agreement With Glucometrics 14
Partnerships 15
Oxygen Biotherapeutics Signs Research Agreement With Hackensack University Medical Center 15
Oxygen Biotherapeutics Enters Into Joint Venture Agreement With Virginia Commonwealth University 16
Licensing Agreements 17
Synthetic Blood International Enters Into Licensing Agreement With Virginia Commonwealth University 17
Equity Offering 19
Oxygen Biotherapeutics Completes Registered Direct Offering Of Common Stock For $5 Million 19
Oxygen Biotherapeutics Completes Second Tranche Of Private Placement Of $3 Million 21
Debt Offering 23
Synthetic Blood Completes Private Placement Of Unsecured Convertible Debentures For $2 Million 23
Key Competitors 24
Key Employees 24
Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Strategy And Business Planning 26
Jun 10, 2010: Oxygen Biotherapeutics Expands Dermacyte Skin Care Sales Territories Into Phoenix And Detroit 26
Financial Announcements 26
Mar 21, 2011: Oxygen Biotherapeutics Reports Net Loss Of $2.5m For Q3 Fiscal 2011 26
Dec 02, 2010: Oxygen Biotherapeutics Reports Net Loss Of $2.1 Million For Q2 Fiscal 2011 27
Sep 09, 2010: Oxygen Biotherapeutics Reports Net Loss Of $3 Million For Q1 Fiscal 2011 27
Jul 23, 2010: Oxygen Biotherapeutics Reports Net Loss Of $10.5 Million For Fiscal 2010 27
Mar 19, 2010: Oxygen Biotherapeutics Reports Net Loss Of $2.8 Million For Q3 Fiscal 2010 28
Dec 11, 2009: Oxygen Biotherapeutics Reports Net Loss Of $2.6 Million For Q2 Fiscal 2010 28
Sep 17, 2009: Oxygen Biotherapeutics Reports Net Loss Of $2.4 Million For Q1 Fiscal 2010 28
Aug 12, 2009: Oxygen Biotherapeutics Reports Net Loss Of $33.2 Million For Fiscal 2009 28
Mar 16, 2009: Oxygen Biotherapeutics Reports Net Loss Of $8.4 Million For Q3 Fiscal 2009 29
Corporate Communications 29
Jun 21, 2010: Oxygen Biotherapeutics Receives Approval For SIX Swiss Exchange Listing 29
Jan 08, 2010: Oxygen Biotherapeutics Receives Approval For NASDAQ Listing 29
Mar 20, 2009: Oxygen Biotherapeutics Appoints New Board Member 30
Apr 10, 2000: Claims Allowed In New Perfluorocarbon Patent 30
Government and Public Interest 30
Oct 20, 2010: DERMACYTE Skin Care Products Secure Key Listing On On-line Skin Care Site 30
Sep 23, 2009: Oxygen Biotherapeutics Receives Approval For Oxycyte 31
Aug 13, 2009: Oxygen Receives Approval To Begin Phase II Trial Of Oxycyte In Switzerland 31
Product News 32
Dec 23, 2008: Oxygen Biotherapeutics, Inc. Submits Information Package To Fda 32
Dec 22, 2006: Synthetic Blood Reports Positive Preliminary Results From Traumatic Brain Injury Clinical Trial 32
Dec 17, 2007: Synthetic Blood Announces Oxycyte Development Strategy 33
Dec 11, 2007: Synthetic Blood Announces Progress With Oxycyte Program In Traumatic Brain Injury 34
Dec 10, 2003: Synthetic Blood International Announces Successful Completion Of Final Dosing In Phase I Study 34
Dec 08, 1997: New Patent For C-10 Perfluorocarbon 35
Dec 04, 2009: Oxygen Biotherapeutics, Inc. Enrolls First Patient In Traumatic Brain Injury Clinical Trial In Switzerland 35
Nov 18, 2003: Synthetic Blood International Announces Completion Of Second Dose Level In Phase I Clinical Study 36
Nov 11, 2003: Synthetic Blood International Announces Completion Of First Dose Level In Phase I Clinical Study 36
Nov 03, 2003: Synthetic Blood International Announces Start Of Oxycyte Phase I Clinical Trial 37
Oct 28, 2008: Oxygen Biotherapeutics, Inc. To Submit Revised Protocol For Oxycyte(R) Clinical Trials In The U.S.A. And Canada 37
Oct 25, 2000: Australia Patent Office Issues Glucose Biosensor Patent 38
Oct 23, 2008: Oxygen Biotherapeutics, Inc. Reports On Fda Meeting, Next Oxycyte(R) Clinical Trial And Development Direction 38
Oct 07, 1997: Patent Issued For Fluorocarbon Developed By Synthetic Blood International 39
Oct 04, 2005: Synthetic Blood To Accelerate Phase Ii Clinical Development Of Oxycyte 39
Sep 28, 1998: New Fluorovent Patent Issued In Australia 40
Sep 24, 2009: Oxygen Biotherapeutics, Inc. Files Patent Application For Emergency Heart Attack Treatment Device 40
Sep 23, 2009: Oxygen Biotherapeutics, Inc. Receives Phase Ii Trial Approval In Israel 41
Sep 23, 2002: Synthetic Blood International Announces Successful Completion Of Key Animal Studies 41
Sep 20, 1999: Synthetic Blood International Files New Biosensor Patent Application 41
Sep 10, 2008: Oxygen Biotherapeutics, Inc. Sets Fda Meeting Date For Proposed Phase Iib Oxycyte Clinical Trial 42
Sep 08, 2009: Oxygen Biotherapeutics, Inc. Submits Milestone Achievement Notice To Vatea Fund 42
Sep 07, 2004: Synthetic Blood International Announces Phase Ii Protocol Submission 42
Aug 31, 1998: Acceptance Of New Pfc Patent 43
Aug 28, 2006: Patient Treatment Completed In Synthetic Blood Traumatic Brain Injury Trial; Oxycyte Administration Increases Brain Oxygen Tension In All Trial Patients; Announcement Of Preliminary Analysis Of Trial Data Expected In 4th Quarter 43
Aug 22, 2005: Synthetic Blood To Initiate Oxycyte Phase Ii Pilot Study In Traumatic Brain Injury 44
Aug 14, 2009: Oxygen Biotherapeutics, Inc. To Begin Oxycyte(R) Phase Ii Clinical Trials In Switzerland 44
Aug 13, 2009: Oxygen Receives Approval To Begin Phase II Trial Of Oxycyte In Switzerland 45
Aug 09, 2006: Two Additional Traumatic Brain Injury Patients Treated In Synthetic Blood Trial 45
Aug 02, 2010: Oxygen Biotherapeutics Signs Crada With U.S. Navy To Study Treatment Of Decompression Sickness Using Oxycyte(R) Emulsion 46
Jul 25, 2005: Tampa General Hospital Approved To Enroll Patients In Synthetic Blood Internationals Phase Ii Oxycyte Trial 46
Jul 23, 2003: Synthetic Blood International Announces Transfer Of Oxycyte Contract Manufacturing 46
Jul 17, 2000: New Australia Patent Issued For Fluorovent 47
Jul 12, 2006: Synthetic Blood Updates Traumatic Brain Injury Trial Enrollment; Six Of Eight Patients Treated In Phase Ii Study 47
Jul 11, 1997: All Claims Approved For Fluorovent Patent 47
Jul 09, 2008: Oxygen Biotherapeutics Provides Update On Recent Events And Phase Iib Oxycyte Clinical Trial 48
Jun 30, 2010: Oxycyte(R) Pfce Decreases Mortality From Decompression Sickness In Preclinical Study 48
Jun 19, 2006: Synthetic Blood Receives Letter Of Intent To Initiate Oxycyte Cardiopulmonary Bypass Surgery Registration Trial In Mexico 49
Jun 14, 2004: Synthetic Blood International Announces Results Of Phase I Study 49
Jun 14, 2000: New Fluorovent Patent 50
Jun 07, 2004: Synthetic Blood International Announces Oxycyte Phase Ii Clinical Trial Plans 50
Jun 03, 2002: Synthetic Blood International Announces Major Financing, Outcome Of Fda Meeting 51
May 24, 1999: Synthetic Blood International, Inc. Requests Shareholder Approval To Issue 10 Million Shares Of Preferred Stock 51
May 23, 2001: Synthetic Blood International Announces Allowance Of Biosensor Patent Application Claims 52
May 19, 2010: Oxygen Biotherapeutics Builds New Relationships For Dermacyte Products And Traumatic Brain Injury Clinical Trials 52
May 19, 2006: Synthetic Blood Reaches First Half Of Traumatic Brain Injury Trial 52
May 15, 2007: Positive Statistical Analysis From Synthetic Bloods Oxycyte Traumatic Brain Injury Trial Indicates Achievement Of Primary Endpoint 53
May 07, 2009: Oxygen Biotherapeutics, Inc. Submits Orphan Drug Application For Oxycyte 53
May 01, 2009: Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement For New Oxycyte-Based Cosmetic Gel 54
Apr 30, 2003: Costa Mesa Company Begins Artificial Blood Trials 54
Apr 21, 2003: Synthetic Blood International, Inc. Announces Fda Approval Of Oxycyte Clinical Protocol 55
Apr 18, 2005: Patients Enrolled In Synthetic Blood International’s Phase Ii Oxycyte Trial 55
Apr 14, 2009: Oxygen Biotherapeutics, Inc. Signs Supply Agreement For Clinical-Grade Oxycyte For Clinical Trials And Future Needs 56
Apr 14, 2008: Synthetic Blood International, Inc. Announces Filing Of Protocol For Phase Ii-B Oxycyte Clinical Trial 56
Apr 13, 1998: New Director Of Preclinical Toxicology And Pharmacology 56
Apr 06, 2006: Three Patients Treated In Synthetic Bloods Traumatic Brain Injury Trial; Brain Oxygen Levels Increase Following Oxycyte Administration 57
Apr 04, 2008: Synthetic Blood International, Inc. Announces Plans To File Protocol For Phase Ii-B Oxycyte(R) Clinical Trial 57
Apr 02, 2003: Synthetic Blood International Announces Response To The Food And Drug Administration 58
Mar 31, 1997: Synthetic Blood International Files New Patent Applications 58
Mar 26, 2009: Oxygen Biotherapeutics, Inc. Adds Oxycyte Tbi Clinical Trial Sites In Israel 58
Mar 17, 2009: Oxygen Biotherapeutics, Inc. To Launch Product Line Of Oxycyte(R) Gels For The Over-The-Counter Market 59
Mar 16, 2006: Synthetic Blood Enrolls First Patient In Phase Ii Traumatic Brain Injury Study 59
Feb 26, 2009: Oxygen Biotherapeutics, Inc. Hires Contract Research Organization And Identifies Swiss Trial Sites For Additional Oxycyte(R) Phase Ii Clinical Trials 59
Feb 25, 1999: Projected Royalty Revenues 60
Feb 20, 2002: Sybd Plans Meeting With Fda To Discuss Oxycyte Clinical Trials 60
Feb 17, 2006: Synthetic Blood Receives Fda Correspondence Concerning Sickle Cell Anemia Trial; Company Expects To Initiate Trial In Second Quarter 61
Feb 16, 1999: Allowance Of Glucose Biosensor Patent Claims 61
Feb 12, 2003: Synthetic Blood International Announces Filing Of Oxycyte Ind 61
Feb 10, 2009: Oxygen Biotherapeutics, Inc. Announces Plans For Additional Oxycyte(R) Phase Ii Clinical Trials 61
Feb 10, 1998: Fluorovent Patent Approval 62
Feb 08, 1999: Biosensor Patent Claims Approved 62
Jan 28, 2011: Oxygen Biotherapeutics And Hackensack University Medical Center Sign Research Contract 62
Jan 27, 2009: Oxygen Biotherapeutics, Inc. Submits Request For Designation To Fda For Oxycyte(R)-Based Wound Care Product 63
Jan 27, 2004: Synthetic Blood International Announces Preliminary Analysis Of Oxycyte Phase I Study Results 63
Jan 26, 2009: Fda Responds To Oxygen Biotherapeutics, Inc. Information Package Regarding Oxycyte(R) Clinical Trials 64
Jan 07, 2004: Synthetic Blood International Announces Preparations For Phase Ii Oxycyte Clinical Testing 64
Jan 06, 2005: Synthetic Blood International Initiates First Phase Ii Oxycyte Trial 64
Appendix 66
Methodology 66
About GlobalData 66
Contact Us 66
Disclaimer 66

List of Tables


List of Tables
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Key Facts, 2010 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 6
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare Deals By Type, 2005 to YTD 2011 7
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011 8
Oxygen Biotherapeutics, Inc., Deals By Therapy Area, 2005 to YTD 2011 9
Oxygen Biotherapeutics, Inc., Medical Devices Deals, 2005 to YTD 2011 10
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 11
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Partnerships, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 11
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 12
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Licensing Deals, Deals By Year Vs Deal Value Vs Upfront Payment, 2005 to YTD 2011 12
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals Summary, 2005 to YTD 2011 13
Oxygen Biotherapeutics Enters Into An Agreement With Glucometrics 14
Oxygen Biotherapeutics Signs Research Agreement With Hackensack University Medical Center 15
Oxygen Biotherapeutics Enters Into Joint Venture Agreement With Virginia Commonwealth University 16
Synthetic Blood International Enters Into Licensing Agreement With Virginia Commonwealth University 17
Oxygen Biotherapeutics Completes Registered Direct Offering Of Common Stock For $5 Million 19
Oxygen Biotherapeutics Completes Second Tranche Of Private Placement Of $3 Million 21
Synthetic Blood Completes Private Placement Of Unsecured Convertible Debentures For $2 Million 23
Oxygen Biotherapeutics, Inc., Key Employees 24
Oxygen Biotherapeutics, Inc., Other Locations 25

List of Figures


List of Figures
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011 1
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2005 to YTD 2011 6
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2005 to YTD 2011 7
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Region, 2005 to YTD 2011 8
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Therapy Area, 2005 to YTD 2011 9
Oxygen Biotherapeutics, Inc., Pharmaceuticals & Healthcare, Medical Devices Deals, 2005 to YTD 2011 10